4530 久光製薬

累計 / 通期：4Q / 3Q / 2Q / 1Q

決算期	四半期	売上高	営業利益	営業利益率	経常利益	経常利益率	純利益	純利益率	EPS	売上高前年比	営業利益前年比	経常利益前年比	純利益前年比
2026/02	4Q	163,024	17,917	11.0%	23,952	14.7%	19,160	11.8%	268.56	4.5%	-5.2%	-0.2%	-11.9%
2025/02	4Q	156,006	18,895	12.1%	24,010	15.4%	21,758	13.9%	295.57	10.1%	43.5%	22.2%	55.8%
2024/02	4Q	141,706	13,167	9.3%	19,649	13.9%	13,969	9.9%	181.62	10.4%	13.5%	22.4%	19.0%
2023/02	4Q	128,330	11,599	9.0%	16,051	12.5%	11,742	9.1%	148.01	6.8%	24.2%	27.0%	21.6%
2022/02	4Q	120,193	9,337	7.8%	12,638	10.5%	9,658	8.0%	118.92	5.0%	-12.5%	6.8%	4.4%
2021/02	4Q	114,510	10,671	9.3%	11,829	10.3%	9,250	8.1%	113.22	-18.8%	-53.0%	-53.8%	-50.5%
2020/02	4Q	140,992	22,727	16.1%	25,628	18.2%	18,694	13.3%	227.58	-1.7%	2.0%	4.0%	-2.7%
2019/02	4Q	143,408	22,278	15.5%	24,647	17.2%	19,204	13.4%	230.08	-	-	-	-

決算期	四半期	売上高	営業利益	営業利益率	経常利益	経常利益率	純利益	純利益率	EPS	売上高前年比	営業利益前年比	経常利益前年比	純利益前年比
2026/02	4Q	163,024	17,917	11.0%	23,952	14.7%	19,160	11.8%	268.56	4.5%	-5.2%	-0.2%	-11.9%
2025/02	4Q	156,006	18,895	12.1%	24,010	15.4%	21,758	13.9%	295.57	10.1%	43.5%	22.2%	55.8%
2024/02	4Q	141,706	13,167	9.3%	19,649	13.9%	13,969	9.9%	181.62	10.4%	13.5%	22.4%	19.0%
2023/02	4Q	128,330	11,599	9.0%	16,051	12.5%	11,742	9.1%	148.01	6.8%	24.2%	27.0%	21.6%
2022/02	4Q	120,193	9,337	7.8%	12,638	10.5%	9,658	8.0%	118.92	5.0%	-12.5%	6.8%	4.4%
2021/02	4Q	114,510	10,671	9.3%	11,829	10.3%	9,250	8.1%	113.22	-18.8%	-53.0%	-53.8%	-50.5%
2020/02	4Q	140,992	22,727	16.1%	25,628	18.2%	18,694	13.3%	227.58	-1.7%	2.0%	4.0%	-2.7%
2019/02	4Q	143,408	22,278	15.5%	24,647	17.2%	19,204	13.4%	230.08	-	-	-	-